Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

BUSPIRONE Tablets (2016)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

BUSPIRONE 5mg TABLETS.

Qualitative and quantitative composition

Each dosage form contains 5mg buspirone hydrochloride. Excipients with known effect: each tablet contains 60.80mg Lactose monohydrate. For the full list of excipients, see section 6.1.

Pharmaceutical form

Tablet. White, uncoated, flat bevelled edge with A5 on one side and plain on the other.

Therapeutic indications

Buspirone is indicated for the treatment of short-term management of anxiety disorders and the relief of symptoms of anxiety with or without accompanying symptoms of depression.

Posology and method of administration

Posology The dosage should be individualised for each patient. Adults (including the elderly): the usual starting dosage is 5mg given two to three times per day. The dosage may be increased every 2-3 days. ...

Contraindications

Buspirone is contraindicated in the following groups of patients. Patients with known hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Patients with epilepsy. ...

Special warnings and precautions for use

The administration of buspirone to a patient taking a monoamine oxidase inhibitor (MAOI) may pose a hazard. There have been reports of the occurrence of elevated blood pressure when buspirone has been ...

Interaction with other medicinal products and other forms of interaction

The concomitant use of buspirone with other CNS-active drugs should be approached with caution. Effect of other drugs on buspirone Association not recommended MAO inhibitors Co-administration of MAO inhibitors ...

Pregnancy and lactation

Pregnancy There are no or limited amount of data from the use of buspirone in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see ...

Effects on ability to drive and use machines

Buspirone has moderate influence on the ability to drive and use machines. Attention is drawn to the risks associated with drowsiness or dizziness induced by this drug (see section 4.8). This medicine ...

Undesirable effects

Side effects of buspirone, if they occur, are generally observed at the beginning of drug therapy and usually subside with use of the medication and/or decreased dosage. Clinical experience When patients ...

Overdose

Features In normal volunteers, the maximum tolerated dose of buspirone was 375 mg/day. As the maximum dose levels were approached, the most commonly observed symptoms include nausea, vomiting, headache, ...

Pharmacodynamic properties

ATC code: NO5BE01 Buspirone is an azaspirodecanedione. The exact mechanism of Buspirone anxioselective action is not fully known. It does not act on benzodiazepine receptor sites and lacks sedative, anticonvulsant ...

Pharmacokinetic properties

Absorption Buspirone hydrochloride is rapidly absorbed from the gastrointestinal tract reaching peak plasma concentrations within 40 to 90 minutes after administration by mouth. Systemic bioavailability ...

Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

List of excipients

Lactose monohydrate Magnesium stearate Purified talc Polyvidone K-25 Potato starch

Incompatibilities

Not applicable.

Shelf life

Shelf life: Three years.

Special precautions for storage

Do not store above 25°C. Store in the original container.

Nature and contents of container

250µm white opaque PVC/20µm aluminium foil blister packs. Blister pack sizes: 20, 21, 28, 30, 56, 60, 84, 90, 100, 112, 126

Special precautions for disposal and other handling

There are no special instructions for use/handling.

Marketing authorization holder

Actavis UK Limited (Trading styles: Actavis), Whiddon Valley, BARNSTAPLE, N Devon EX32 8NS

Marketing authorization number(s)

PL 0142/0455

Date of first authorization / renewal of the authorization

24 July 2002 / 23 January 2009

Date of revision of the text

14/07/2016

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: